Abstract
The utility of cognitive-behavioral therapy in the treatment of acute depression has been well established. It is frequently employed with antidepressants acutely to yield greatest efficacy. While it is frequently stated that the techniques of CBT learned during acute treatment are enduring, there is little data suggesting that this is true.
We studied 327 patients over a 13 year period in a community clinic who responded to one of four Selective Serotonin Reuptake Inhibitors (SSRI's) with a 50% reduction in Montgomery Asberg Score after 12 weeks treatment. SSRI's used were fluoxetine, citalopram, paroxetine and sertraline. The patients were all followed on the medication to which they responded until they either relapsed, dropped out, or terminated well (were well as of September 1, 2005 the endpoint of the study).
Overall, 110 patients acutely received CBT in addition to the SSRI and 217 did not. Following acute response 35 of the 110 patients who received CBT acutely elected to continue CBT in addition to the medication and 75 did not. Overall, the group that continued CBT remained well for 49.60 months as opposed to 34.77 months for those who did not continue CBT vs 30.78 months for those who only received drug alone. Pairwise comparisons using the Scheffe show that longterm CBT results in significantly more time of stability than either acute CBT (p=.039) or drug alone (p=.001). Acute CBT and Drug Alone did not differ significantly from each other (p=0.58).. Interestingly the 75 patients who received CBT acutely but not for maintenance did not remain well longer than the 217 patients who did not receive CBT acutely (34.77 vs 30.78 p=0.58).
In conclusion, CBT in addition to medication during acute treatment did not endure for the long-term. However maintenance CBT in addition to SSRI's was effective in preventing relapse.
Keywords: Cognitive behavioral therapy (CBT), continuation therapy, selective serotonin inhibitors (SSRI).
Current Psychopharmacology
Title:Maintenance CBT in Preventing Relapse in Patients on SSRI Continuation
Volume: 2
Author(s): Eric D. Peselow
Affiliation:
Keywords: Cognitive behavioral therapy (CBT), continuation therapy, selective serotonin inhibitors (SSRI).
Abstract: The utility of cognitive-behavioral therapy in the treatment of acute depression has been well established. It is frequently employed with antidepressants acutely to yield greatest efficacy. While it is frequently stated that the techniques of CBT learned during acute treatment are enduring, there is little data suggesting that this is true.
We studied 327 patients over a 13 year period in a community clinic who responded to one of four Selective Serotonin Reuptake Inhibitors (SSRI's) with a 50% reduction in Montgomery Asberg Score after 12 weeks treatment. SSRI's used were fluoxetine, citalopram, paroxetine and sertraline. The patients were all followed on the medication to which they responded until they either relapsed, dropped out, or terminated well (were well as of September 1, 2005 the endpoint of the study).
Overall, 110 patients acutely received CBT in addition to the SSRI and 217 did not. Following acute response 35 of the 110 patients who received CBT acutely elected to continue CBT in addition to the medication and 75 did not. Overall, the group that continued CBT remained well for 49.60 months as opposed to 34.77 months for those who did not continue CBT vs 30.78 months for those who only received drug alone. Pairwise comparisons using the Scheffe show that longterm CBT results in significantly more time of stability than either acute CBT (p=.039) or drug alone (p=.001). Acute CBT and Drug Alone did not differ significantly from each other (p=0.58).. Interestingly the 75 patients who received CBT acutely but not for maintenance did not remain well longer than the 217 patients who did not receive CBT acutely (34.77 vs 30.78 p=0.58).
In conclusion, CBT in addition to medication during acute treatment did not endure for the long-term. However maintenance CBT in addition to SSRI's was effective in preventing relapse.
Export Options
About this article
Cite this article as:
Peselow D. Eric, Maintenance CBT in Preventing Relapse in Patients on SSRI Continuation, Current Psychopharmacology 2013; 2 (3) . https://dx.doi.org/10.2174/2211556002666131203232012
DOI https://dx.doi.org/10.2174/2211556002666131203232012 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pulse of Drug Development for Alzheimers Disease
Reviews on Recent Clinical Trials Kv1.3 Lymphocyte Potassium Channel Inhibition as a Potential Novel Therapeutic Target in Acute Ischemic Stroke
CNS & Neurological Disorders - Drug Targets A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems
Current Pharmaceutical Design Ketamine-Induced Neurotoxicity and Changes in Gene Expression in the Developing Rat Brain
Current Neuropharmacology Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity
Current Drug Metabolism Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases
Current Drug Targets - CNS & Neurological Disorders Commentary [ Research Highlights(To miR or Not to miR: That is the Question in ALS Disease ]
CNS & Neurological Disorders - Drug Targets Cannabis use and Duration of Untreated Psychosis: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Role of Antioxidants Treatments on Oxidative Stress and Calcium Entry in Neurological Disease: Focus on TRP Channels)
Current Neuropharmacology A Relationship between Endothelial Nitric Oxide Synthetase Gene Variants and Substance Use Disorder
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet Our Editorial Board Member:
CNS & Neurological Disorders - Drug Targets BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Serotonin Receptors, Type 4: A New Hope?
Current Drug Targets Assessing Personality Disorders in Adolescence: A Validation Study of the IPOP-A
Adolescent Psychiatry Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles
Current Pharmaceutical Design Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia Histone Acetylation in Neurodevelopment
Current Pharmaceutical Design Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review
Letters in Drug Design & Discovery